AI for Biopharmaceutical R&D: From Searching for Information to Acting on It

Drug development has always been a knowledge problem as much as a science problem. The biology and chemistry of discovering a viable drug candidate are formidable. But the organizational challenge — ensuring that the scientists and regulatory specialists doing that work have access to the full body of relevant knowledge at the moment they need it — is where biopharma organizations consistently lose time and money they cannot afford to lose.

The numbers are well documented. A new drug takes an average of ten to fifteen years from discovery to market approval. Development costs regularly exceed $1 billion per approved compound, accounting for the cost of failures along the way. Patent cliffs create relentless pressure to replace revenue as exclusivity expires. In this environment, the cost of a scientist spending three days finding an answer that exists in the organization’s own data, or of a clinical team repeating work that was already done in a prior trial, is not an abstract inefficiency — it is a measurable drag on competitive position and pipeline velocity.

The organizations gaining ground on this problem are not doing it by hiring more scientists or running faster searches. They are doing it by deploying enterprise AI agents and RAG-enabled knowledge systems that make the full depth of their scientific, clinical, and regulatory knowledge accessible in real time — to every researcher, every regulatory specialist, every clinical operations team member who needs it.

The Biopharma Knowledge Problem Is Unique in Its Complexity

Every large enterprise has a data problem. Biopharma’s version is distinctive in ways that matter for AI deployment.

The volume is extraordinary. A single global pharmaceutical company generates terabytes of scientific content annually: laboratory notebooks, experimental results, clinical study reports, safety data, regulatory submissions, literature references, patent filings, and the accumulated research output of thousands of R&D professionals across multiple therapeutic areas and global sites. According to research from the National Institutes of Health, the biomedical literature doubles approximately every nine years — and that is only the external published literature, not internal organizational knowledge.

The regulatory dimension adds another layer of complexity. Biopharma organizations must maintain compliance with FDA, EMA, ICH guidelines, GxP requirements, and a matrix of jurisdiction-specific regulations that evolve continuously. The knowledge required to navigate regulatory submissions, respond to agency queries, and maintain compliance documentation is itself a specialized discipline — and one where the cost of a gap in knowledge is measured in approval delays, not just inefficiency.

The access control requirement is more stringent than in most industries. Clinical trial data, safety signals, competitive intelligence, and pre-submission regulatory strategy all carry confidentiality obligations that make information governance a primary concern. Enterprise AI security in biopharma must enforce access controls at the retrieval layer — ensuring that AI systems surface only the information each user is authorized to access, regardless of how a query is phrased.

And the knowledge is distributed across systems and formats that resist unified access: electronic lab notebooks (ELNs), laboratory information management systems (LIMS), document management platforms, clinical data repositories, regulatory archives, and the scientific literature. No single system contains the full picture for any significant research question.

Four Workflows Where Enterprise AI Is Accelerating Biopharma R&D

Expert Discovery and Team Assembly

Large biopharma organizations face a persistent structural challenge: the expertise required for any given research project is distributed across a global organization with thousands of scientists, organized into therapeutic areas, functional groups, and site-specific teams that rarely have full visibility into what each other knows.

A drug repositioning project — exploring whether a compound developed for one indication might address another — typically requires expertise across related molecules, mechanisms of action, clinical pharmacology, translational science, and the regulatory history of the compound in question. Identifying which colleagues have directly relevant experience, and which of their prior projects are most applicable, is a weeks-long process through informal networks and organizational directories when done manually.

Enterprise AI agents trained on the organization’s scientific output — publications, study reports, patent filings, experimental records — can identify expert profiles based on actual documented contributions rather than self-reported credentials. A scientist working on a new oncology indication can identify colleagues with directly relevant molecular experience, find the studies they contributed to, and surface the specific findings from those studies in minutes rather than weeks. The result is faster team assembly, more complete cross-functional knowledge, and less duplication of work already done elsewhere in the organization.

Clinical Trial Data Access and Synthesis

Clinical trials generate the most valuable and the most inaccessible data in the biopharma knowledge environment. A major Phase III trial produces millions of data points across patient populations, timepoints, endpoints, and safety parameters. Biostatisticians working with that data traditionally query it at the metadata level — searching the index of what the data contains, not the data itself.

Advanced RAG changes this by enabling AI-powered synthesis across clinical data repositories in ways that keyword search and metadata queries cannot support. A biostatistician can ask, in natural language, for the full patient population across all trials sharing a specific disease criterion and treatment profile — and receive a synthesized answer drawing on the actual data across multiple studies, not just the metadata summary of what each study contains. A clinical operations team can query the trial history for relevant safety signals, dosing precedents, and enrollment parameters relevant to a new protocol design, surfacing information from multiple prior trials simultaneously.

One unnamed global biopharma organization Sinequa worked with achieved a 9X improvement in information findability and accuracy following enterprise AI deployment — a result that reflects the step change between keyword metadata search and AI-powered semantic access to the actual clinical knowledge base. With the ability to search hundreds of patient criteria simultaneously, the organization was able to improve clinical trial design and reduce the time required to identify eligible patient populations for new studies.

R&D Knowledge Access and Reuse

Scientific knowledge in a large biopharma organization has a short half-life of accessibility. Research conducted three years ago is effectively invisible to scientists hired two years ago — unless it was published externally, where it is at least findable in literature databases. Internal research that informed a compound decision, a formulation choice, or a biomarker strategy often lives in systems that new team members do not know to search, in formats that standard search tools cannot process, or simply buried in document management systems with naming conventions that do not surface relevance.

The practical cost of this inaccessibility is repeated work: experiments that reproduce results already documented internally, formulation decisions made without awareness of relevant prior failures, literature reviews that duplicate internal scientific intelligence already captured in prior research summaries.

UCB, the global biopharmaceutical company, documented $143M per year in value from improved scientific knowledge access across its R&D organization — a result that reflects the compounded impact of better-informed research decisions made at scale, across a large and complex scientific organization spanning multiple therapeutic areas and global sites.

Ferring Pharmaceuticals deployed Sinequa with Atos as the implementation partner to give its Global Pharmaceutical R&D group access to vast scientific research datasets — enabling researchers to surface relevant findings, identify connected expertise, and build on prior work across the organization’s full knowledge base rather than the subset visible in any single system.

Regulatory Intelligence and Submission Readiness

Regulatory affairs in biopharma is a knowledge-intensive discipline where the cost of a gap is measured in approval timelines. A regulatory submission requires synthesizing clinical evidence, nonclinical data, CMC (Chemistry, Manufacturing, and Controls) documentation, and the prior regulatory history of the compound — across years of accumulated submissions, agency correspondence, and internal review documentation.

AI-powered research and regulatory intelligence changes how regulatory teams work. Rather than manually assembling the relevant prior correspondence, submission history, and precedent cases for an agency response, regulatory specialists can query the full regulatory knowledge base in natural language — asking which prior submissions addressed a specific safety question, what language was used in analogous indication applications, or which prior agency interactions established the evidentiary standard for a specific endpoint.

The impact is measurable in submission quality as well as speed: regulatory teams with access to the full body of their organization’s regulatory history are better positioned to anticipate agency questions and pre-empt information requests that otherwise cause approval delays.

The GxP Consideration: AI That Meets the Compliance Standard

For biopharma AI deployments, GxP compliance is not an afterthought — it is a prerequisite. Any AI system that supports clinical data access, regulatory submission preparation, or quality management workflows operates in a GxP context, which means the system’s outputs must be auditable, its data sources must be validated, and its access controls must be documented and enforceable.

Enterprise AI in biopharma must therefore provide citation-grounded responses — every AI-generated synthesis must be traceable to the specific source documents that informed it, so that regulatory submissions and quality decisions can be verified against the underlying evidence. Systems that generate answers without auditable provenance are not deployable in GxP contexts regardless of their apparent accuracy.

This auditability requirement is one of the technical differentiators that separates enterprise-grade biopharma AI from general-purpose AI tools adapted for life sciences use.